Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 1/20 | 0.84 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.84 |
| ▸ | PAK4 | O96013 | 1/20 | 0.84 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.84 |
| ▸ | LCK | P06239 | 1/20 | 0.84 |
| ▸ | FYN | P06241 | 1/20 | 0.84 |
| ▸ | CSF1R | P07333 | 1/20 | 0.84 |
| ▸ | RET | P07949 | 1/20 | 0.84 |
| ▸ | IGF1R | P08069 | 1/20 | 0.84 |
| ▸ | MET | P08581 | 1/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.84 |
| ▸ | PRKACA | P17612 | 1/20 | 0.84 |
| ▸ | FLT1 | P17948 | 1/20 | 0.84 |
| ▸ | LTK | P29376 | 1/20 | 0.84 |
| ▸ | KDR | P35968 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12528959 | 0.91 | PTK2 (0.84) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12529526 | 0.89 | PTK2 (0.80) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12528966 | 0.89 | PTK2 (0.80) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12529148 | 0.89 | PTK2 (1.00) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12528928 | 0.88 | PTK2 (1.00) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12529042 | 0.88 | PTK2 (1.00) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12529057 | 0.88 | PTK2 (1.00) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12529051 | 0.88 | PTK2 (1.00) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12529102 | 0.88 | PTK2 (1.00) | PTK2JAK2AURKADAPK3PAK4 | |
| SCHEMBL12529002 | 0.87 | PTK2 (0.77) | PTK2JAK2AURKADAPK3PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968557-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | disclosed |
| US-7968557-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | disclosed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ABL1, PDGFRA, PDGFRB | PTK2 5/4885JAK2 4/4885AURKA 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.